Why Do Some Respond Better to GLP-1 Drugs? Galectin-3 May Offer a Clue
Why do two patients with similar metabolic profiles sometimes respond so differently to the same GLP-1 medication? Galectin-3 may offer an important clue. This emerging biomarker provides insight into the inflammatory and fibrotic “metabolic terrain” that may influence GLP-1 treatment response.